文献速递临床试验与 GCP流行病学与生物统计

32周前重复产前皮质类固醇剂量的二十年结局:一项随机临床试验的随访

Twenty-year outcomes after repeat doses of antenatal corticosteroids prior to 32 weeks' gestation: Follow-up of a randomised clinical trial.
PubMed 文献 · PLoS Med · 2025-05-28

对ACTORDS随机对照试验中新西兰参与者的后代进行20年随访,评估32周前重复产前倍他米松暴露对成年期呼吸及总体健康的影响。主要结局任何哮喘诊断在重复倍他米松组与安慰剂组相似(54% vs 47%;校正风险比1.13,95%CI 0.87-1.46)。结论提示重复产前皮质类固醇对成年早期既无重大危害也无明显获益,不能排除较小效应,建议对其他试验的成年后代进行随访。

要点

  • 32周前重复产前倍他米松暴露与安慰剂相比,成年期任何哮喘诊断率相似(54% vs 47%)。
  • 次要结局组间差异一般较小,置信区间包含组间无差异的可能性。
  • 结论提示重复产前皮质类固醇对成年早期既无重大危害也无明显获益,不能排除较小效应。

核心结论

  • 本随机临床试验随访数据提示,与单疗程相比,32周前暴露于重复剂量产前皮质类固醇的后代在成年早期既无重大危害也无明显获益。
  • 不能排除较小效应,建议对其他重复产前皮质类固醇试验的成年后代进行随访。

研究设计与样本

  • 本研究为ACTORDS多中心安慰剂对照随机临床试验的20年随访,纳入新西兰参与者的成年后代。
  • ACTORDS中,在收到单疗程皮质类固醇后7天或更长时间、未来一周内有早产风险的孕妇被随机分配接受重复剂量肌内倍他米松或安慰剂,若持续存在早产风险可每周重复。
  • 随访包含健康问卷及同意访问行政数据源;290名母亲所生的352名婴儿中,评估了214名(61%;96名(45%)为女性),平均(标准差)年龄20.5(1.5)岁。

主要发现

  • 主要结局任何哮喘诊断率在两组相似:重复倍他米松组58/107(54%)vs 安慰剂组50/107(47%);校正入组时孕龄、多胎和出生中心的风险比为1.13(95%CI 0.87-1.46)。
  • 次要结局包括神经发育、心血管、精神与总体健康、功能困难及社会结局,组间差异一般较小,置信区间包含组间无差异的可能性。

局限性

  • 不能排除较小效应。
  • 建议对其他重复产前皮质类固醇试验的成年后代进行随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For women who have received a course of antenatal corticosteroids ≥7 days prior and have ongoing risk of preterm birth within the next 7 days, repeat dose(s) of corticosteroids up to 32 weeks' gestation have been shown to reduce neonatal respiratory distress syndrome and serious health problems in the neonatal period but not other neonatal morbidities such as chronic lung disease, death, severe intraventricular haemorrhage or necrotising enterocolitis. Repeat antenatal corticosteroids were not associated with either benefit or harms in mid-childhood. However, this may have been too early to evaluate potential adverse effects on respiratory and other long-term outcomes. We aimed to assess if exposure to repeat dose(s) of antenatal corticosteroids administered to pregnant women up to 32 weeks' gestation has beneficial or harmful effects on respiratory and general health of the offspring in adulthood. METHODS AND FINDINGS: We assessed the adult offspring of New Zealand participants in the Australasian Collaborative Trial of Repeat Doses of Corticosteroids for the Prevention of Neonatal Respiratory Disease (ACTORDS), a multicentre, placebo-controlled trial where women at risk of preterm birth within the next week, 7 or more days after having received a single course of corticosteroids were randomised to a repeat dose of intramuscular betamethasone or placebo, that could be repeated weekly if at ongoing preterm birth risk. Follow-up at 20 years included a health questionnaire and consent to access administrative data sources. The primary outcome was any asthma diagnosis. Secondary outcomes included neurodevelopmental, cardiovascular, mental and general health, functional difficulties and social outcomes. Of 352 infants born to 290 maternal trial participants, we assessed 214 (61%; 96 (45%) female) at mean (standard deviation) age 20.5 (1.5) years. The rate of any asthma diagnosis was similar in both groups (58/107 (54%) repeat bethamethasone versus 50/107 (47%) placebo; risk ratio adjusted for gestational age at trial entry, multiplicity and birth centre 1.13, 95% confidence interval, 0.87, 1.46). Differences between the groups for the secondary outcomes were generally small and confidence intervals included the possibility of no difference between groups. CONCLUSIONS: In this follow-up of a randomised clinical trial, our data suggest neither major harm nor benefit for the offspring in early adulthood following exposure to repeat dose(s) of antenatal corticosteroids compared with a single course prior to 32 weeks' gestation. Smaller effects cannot be excluded and follow-up of adult offspring from other trials of repeat antenatal corticosteroids is recommended. TRIAL REGISTRATION: International Standard Randomized Controlled Trial, number ISRCTN48656428.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. May RW, Walters AGB, Gamble GD, et al. Twenty-year outcomes after repeat doses of antenatal corticosteroids prior to 32 weeks' gestation: Follow-up of a randomised clinical trial. PLoS Med. 2025. PMID: 40435347. doi:10.1371/journal.pmed.1004618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。